Eisai is a development-based pharmaceutical company headquartered in Tokyo, with specialisms in oncology and neurology. Now, Eisai is partnering with Numab Therapeutics AG to develop new immunotherapies for cancer.
Under the terms of the agreement, Eisai will use Numab’s MATCH platform to discover highly versatile antibodies with novel mechanisms of action, superior efficacy and good safety profiles, according to a statement.
Eisai has the option to acquire an exclusive license to develop and commercialize novel multi-specific antibody-based molecules that emerge from their research collaboration, explains the statement. In exchange, Numab will receive from Eisai an upfront payment and research funding, and is eligible to receive milestone payments and tiered royalties on sales.
Numab was founded in 2011 and is headquartered in Wädenswil. The company specializes in the development of multi-specific biotherapeutics for immuno-oncology and immunology. It uses its MATCH platform for in-house product development, and provides it to partners in the pharma sector.
Weitere News
Contact us
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?
info@greaterzuricharea.com